Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 49,300 shares, a drop of 40.6% from the February 28th total of 83,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is currently 0.0 days. Currently, 6.6% of the shares of the stock are short sold.

Windtree Therapeutics Trading Down 4.9 %

Shares of NASDAQ WINT opened at $1.56 on Friday. The company has a 50-day moving average of $4.74 and a 200 day moving average of $33.14. Windtree Therapeutics has a 12-month low of $1.45 and a 12-month high of $737.44. The stock has a market cap of $1.17 million, a PE ratio of -0.09 and a beta of 0.68.

Institutional Investors Weigh In On Windtree Therapeutics

An institutional investor recently bought a new position in Windtree Therapeutics stock. Renaissance Technologies LLC acquired a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned about 1.08% of Windtree Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 29.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $350.00 target price on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.